NoEndium Pharmaceuticals

Utilizing a novel target to develop new therapeutic treatments for Hematological disorders

  • Stage Product In Development
  • Industry Biotechnology
  • Location Sudbury, MA, USA
  • Currency USD
  • Founded November 2010
  • Employees 1
  • Website noendium.com

Company Summary

Delivering a paradigm shift in Hematological disorder treatment options by targeting a new Siglec as well as combinations of Siglec(s) utilizing Antibody based treatments that are produced and dosed according to a patients Siglec profile providing the potential for ‘personalized’ treatment regimes

Team

  • James Evans
    President and Founder

    James Evans

    Most recently James was the Associate Director at the Novartis-MIT Center for Continuous Manufacturing, PhD in Chemical Engineering from Heriot Watt University, UK. James has worked in both R&D and Manufacturing for a number of companies including GSK, Vertex Pharmaceuticals and DSM and is currently studying part time at the Sloan school of management.

  • James Evans

Advisors

  • Goodwin and Proctor
    Lawyer
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free